[Current research advance on cellular immunotherapy for leukemia-review].

Abstract

Despite the chemotherapy is successful in inducing remission of hematologic malignancy, this disease also has a high probability of relapse; besides, the toxicity of chemotherapy for these patients can not be avoided. Researchers have been attempting to eliminate tumor cells by immunotherapy. Recently, various leukemia-associated antigens (LAA) that are recognized by cytotoxic T cell (CTL) in the context of HLA class I molecules have been identified. These LAA include WT1, PR-3, RHAMM, BCR-ABL and Aur-A. On the basis of these findings, various clinical trials of immunotherapy for hematologic malignancy including tumor peptide vaccination, adoptive T cell therapy, NK cell therapy and dendritic cells-cytokine induced killer (DC-CIK) cell therapy are on going. In this review, the current status and future feasibility of cellular immunotherapy for leukemia are discussed.

• Authors: Hong Tian, Guang-Hua Chen, Yang Xu, Man Qiao, Hui-Wen Liu, De-Pei Wu
• Journal: Zhongguo shi yan xue ye xue za zhi (Zhongguo Shi Yan Xue Ye Xue Za Zhi) Vol. 21 Issue 5 Pg. 1326-30 (Oct 2013) ISSN: 1009-2137 [Print] China
• PMID: 24156459 (Publication Type: English Abstract, Journal Article, Research Support, Non-U.S. Gov't, Review)

Topics

• Humans
• Immunotherapy, Adoptive
• Leukemia (therapy)
• T-Lymphocytes, Cytotoxic (immunology)